The European Vasculitis Society 2016 Meeting Report.
The European Vasculitis Society 2016 Meeting Report.
复制标题
DOI：
10.1016/j.ekir.2017.09.008
复制
发表时间：
2017-11
影响因子：
6
通讯作者：
Jayne D
中科院分区：
文献类型：
--
作者：
Bajema IM;Bruijn JA;Casian A;Cid MC;Csernok E;van Daalen E;Harper L;Hauser T;Little MA;Luqmani RA;Mahr A;Ponte C;Salama A;Segelmark M;Suzuki K;Sznajd J;Teng YKO;Vaglio A;Westman K;Jayne D
在荷兰莱顿举行的2016年欧洲血管炎学会（EUVAS）会议围绕抗神经细胞胞质抗体（ANCA）相关血管炎（AAV）的表型亚型。EUVAS花瓣有平行会议，在这里报告疾病评估;数据库;和长期随访，登记，遗传学，组织学，生物标志物研究和临床试验。目前进行的研究将提高我们区分不同形式血管炎的能力。在一个涉及AAV患者10年随访的项目中，我们正在检索患者和肾脏存活率、复发率、恶性肿瘤累积发生率和合并症的数据。在整个欧洲，开发了几个血管炎登记系统，涵盖了10，000多名登记患者。在不久的将来，这些登记将促进AAV的临床研究，其规模迄今为止尚不清楚。目前对AAV遗传背景的研究将探索遗传标记的潜在预后意义，并进一步完善与不同疾病子集的遗传关联。ANCA相关性肾小球肾炎的组织病理学分类目前正在根据一项大型国际验证研究的数据进行评估。在我们不断寻找生物标志物来预测临床结果的过程中，有前途的新标志物是当前研究的重要课题。在过去的20年里，大量的临床试验为治疗方案的改进提供了证据。我们给出了目前正在开发的临床试验的概述，并详细考虑了难治性血管炎。EUVAS的目标是刺激针对系统性血管炎患者的临床、血清学和组织学管理和技术的持续研究，并展望临床试验的适用性。
The 2016 European Vasculitis Society (EUVAS) meeting, held in Leiden, the Netherlands, was centered around phenotypic subtyping in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV). There were parallel meetings of the EUVAS petals, which here report on disease assessment; database; and long-term follow-up, registries, genetics, histology, biomarker studies, and clinical trials. Studies currently conducted will improve our ability to discriminate between different forms of vasculitis. In a project that involves the 10-year follow-up of AAV patients, we are working on retrieving data on patient and renal survival, relapse rate, the cumulative incidence of malignancies, and comorbidities. Across Europe, several vasculitis registries were developed covering over 10,000 registered patients. In the near future, these registries will facilitate clinical research in AAV on a scale hitherto unknown. Current studies on the genetic background of AAV will explore the potential prognostic significance of genetic markers and further refine genetic associations with distinct disease subsets. The histopathological classification of ANCA-associated glomerulonephritis is currently evaluated in light of data coming out of a large international validation study. In our continuous search for biomarkers to predict clinical outcome, promising new markers are important subjects of current research. Over the last 2 decades, a host of clinical trials have provided evidence for refinement of therapeutic regimens. We give an overview of clinical trials currently under development, and consider refractory vasculitis in detail. The goal of EUVAS is to stimulate ongoing research in clinical, serological, and histological management and techniques for patients with systemic vasculitis, with an outlook on the applicability for clinical trials.
登录
查看更多内容
影响因子：
30.8
作者：
通讯作者：
--
影响因子：
27.4
作者：
Harper, Lorraine;Morgan, Matthew D.;Jayne, David
通讯作者：
Jayne, David
影响因子：
12.8
作者：
Calich, Ana Luisa;Puechal, Xavier;Guillevin, Loic
通讯作者：
Guillevin, Loic
影响因子：
19.6
作者：
Hauer, HA;Bajema, IM;Hagen, EC
通讯作者：
Hagen, EC
影响因子：
27.4
作者：
Flossmann, Oliver;Berden, Annelies;Westman, Kerstin
通讯作者：
Westman, Kerstin